Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines.

por Boven, E., Erkelens, C. A., Luning, M., Pinedo, H. M.
Publicado 1990

The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

por Boven, E., Hendriks, H. R., Erkelens, C. A., Pinedo, H. M.
Publicado 1992

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

por Boven, E., Schipper, H., Erkelens, C. A., Hatty, S. A., Pinedo, H. M.
Publicado 1993

Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.

por Nauta, M. M., Boven, E., Schlüper, H. M., Erkelens, C. A., Pinedo, H. M.
Publicado 1986

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats

por Verschraagen, M, Boven, E, Torun, E, Erkelens, C A M, Hausheer, F H, van der Vijgh, W J F
Publicado 2004

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

por Houba, P. H., Boven, E., Erkelens, C. A., Leenders, R. G., Scheeren, J. W., Pinedo, H. M., Haisma, H. J.
Publicado 1998

Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.

por Boven, E., Pinedo, H. M., van Hattum, A. H., Scheffer, P. G., Peters, W. H., Erkelens, C. A., Schlüper, H. M., Kuiper, C. M., van Ark-Otte, J., Giaccone, G.
Publicado 1998